FDA Evaluating Orlistat For Potential Serious Risks
This article was originally published in The Tan Sheet
Executive Summary
FDA is evaluating whether recent adverse event reports of rectal bleeding signal a potential serious risk identified with orlistat - the active ingredient in Roche's Rx diet drug Xenical and GlaxoSmithKline's OTC weight-loss product alli